Cancers, Free Full-Text

Despite a few cases of long-responder patients, immunotherapy with anti-PD-(L)1 has so far proved rather disappointing in monotherapy in metastatic breast cancer, prompting the use of synergistic therapeutic combinations incorporating immunotherapy by immune-checkpoint inhibitors. In addition, a better understanding of both the mechanisms of sensitivity and resistance to immunotherapy, as well as the immunological effects of the usual treatments for breast cancer, make it possible to rationally consider this type of therapeutic combination. For several years, certain treatments, commonly used to treat patients with breast cancer, have shown that in addition to their direct cytotoxic effects, they may have an impact on the tumor immune microenvironment, by increasing the antigenicity and/or immunogenicity of a “cold” tumor, targeting the immunosuppressive microenvironment or counteracting the immune-exclusion profile. This review focuses on preclinical immunologic synergic mechanisms of various standard therapeutic approaches with anti-PD-(L)1, and discusses the potential clinical use of anti-PD-1/L1 combinations in metastatic or early breast cancer.

Characteristics of the breast cancer-free female cohort

Stream World Rose Day

Cancers, Free Full-Text, hana hana no mi awakening

Buckeyes for a Cancer Free World' football game promotes 'all

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and

Cancers, Free Full-Text

IJMS, Free Full-Text, mdpope 1-3

ACF not offering free surgeries to breast cancer patients